These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21308501)

  • 21. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
    Young K; Liu B; Bhuket T; Gish RG; Wong RJ
    J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy.
    Lockart I; Hajarizadeh B; Buckley N; Davison S; Prakoso E; Levy MT; George J; Dore GJ; Danta M
    J Gastroenterol Hepatol; 2021 Dec; 36(12):3515-3523. PubMed ID: 34520088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
    Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A
    Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
    Lim T
    Hepat Med; 2014; 6():113-8. PubMed ID: 25506251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved Hepatitis C Cure Cascade Outcomes Among Urban Baby Boomers in the Direct-Acting Antiviral Era.
    Dupont SC; Fluker SA; Quairoli KM; Body C; Okosun I; Lom J; Miller LS
    Public Health Rep; 2020 Jan; 135(1):107-113. PubMed ID: 31756116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
    Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
    Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era.
    Valerio H; McAuley A; Innes H; Palmateer N; Goldberg DJ; Munro A; Taylor A; Hutchinson SJ
    Int J Drug Policy; 2018 Feb; 52():115-122. PubMed ID: 29414462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can hepatitis C virus infection be eradicated in people who inject drugs?
    Grebely J; Dore GJ
    Antiviral Res; 2014 Apr; 104():62-72. PubMed ID: 24468275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world.
    Donaldson SR; Radley A; Dillon JF
    Subst Abuse Treat Prev Policy; 2022 Jun; 17(1):45. PubMed ID: 35676732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination.
    Virlogeux V; Zoulim F; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
    BMC Med; 2017 Dec; 15(1):217. PubMed ID: 29249202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of interferon in the new era of hepatitis C treatments.
    Parekh PJ; Shiffman ML
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):649-56. PubMed ID: 24758387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era.
    Li AA; Cholankeril G; Cheng XS; Tan JC; Kim D; Toll AE; Nair S; Ahmed A
    Diseases; 2018 Jul; 6(3):. PubMed ID: 29996536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changing Population of Liver Transplant Recipients in the Era of Direct-acting Antiviral Therapy.
    Xie C; Kuo YF; Singal AK
    J Clin Transl Hepatol; 2020 Sep; 8(3):262-266. PubMed ID: 33083248
    [No Abstract]   [Full Text] [Related]  

  • 34. Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.
    Wong GL; Chan HL; Loo CK; Hui YT; Fung JY; Cheung D; Chung C; Chim AM; Wong VW;
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1641-1647. PubMed ID: 30707777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?
    Bunchorntavakul C; Mitrani R; Reddy KR
    J Clin Exp Hepatol; 2018 Mar; 8(1):81-94. PubMed ID: 29743799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Hepatitis C Virus Infection on Heart Transplants in the Current Era.
    Fujisaki T; Mikami T; Kuno T; Moss N; Itagaki S
    Transplantation; 2021 Nov; 105(11):2482-2489. PubMed ID: 33496557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic outcome of 6198 interferon-naïve Egyptian patients with chronic hepatitis C: a real-life experience and lessons to be learned in DAAs' era.
    Zayed N; Gamal Eldeen H; Elmakhzangy H; Seif M; El-Akel W; Awad T; Esmat G; Mabrouk M
    J Viral Hepat; 2016 Jul; 23(7):506-11. PubMed ID: 26936687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients.
    Wong YJ; Thurairajah PH; Kumar R; Fock KM; Law NM; Chong SY; Manejero FG; Ang TL; Teo EK; Tan J
    Clin Mol Hepatol; 2021 Jul; 27(3):474-485. PubMed ID: 33601868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostics for resource-limited settings in the era of interferon-free HCV therapy.
    Cooke GS; Hill AM
    J Viral Hepat; 2015 May; 22(5):459-60. PubMed ID: 25727262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C virus media coverage favorably impacts on antibody testing in the non-interferon era.
    Morales-Arraez D; Hernandez-Guerra M; Diaz-Flores F; Nieto-Bujalance Y; Garcia-Dopico J; Jimenez A; Quintero E
    J Public Health (Oxf); 2021 Jun; 43(2):385-391. PubMed ID: 31786606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.